Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 351252, 7 pages
http://dx.doi.org/10.1155/2014/351252
Clinical Study

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

1Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
2Diagnostic Oncology Department, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
3Biostatistic Unit, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
4Division of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy
5Division of Neurosurgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
6Department of Pathology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
7Division of Neurology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
8Department of Radiation Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy

Received 14 February 2014; Revised 9 April 2014; Accepted 14 April 2014; Published 4 May 2014

Academic Editor: Roberta Rudà

Copyright © 2014 V. Vaccaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

V. Vaccaro, A. Fabi, A. Vidiri, et al., “Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas,” BioMed Research International, vol. 2014, Article ID 351252, 7 pages, 2014. https://doi.org/10.1155/2014/351252.